Catalyst Pharmaceuticals, Inc. (CPRX)

Market Cap	2.82B +7.3%
Revenue (ttm)	588.99M +19.8%
Net Income	214.33M +30.8%
EPS	1.68 +28.2%
Shares Out	122.12M
PE Ratio	13.76
Forward PE	12.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	259,740
Open	23.22
Previous Close	23.32
Day's Range	22.92 - 23.34
52-Week Range	19.05 - 26.58
Beta	0.71
Analysts	Strong Buy
Price Target	35.00 (+51.35%)
Earnings Date	May 6, 2026

About CPRX

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticoste...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 2006
• Employees: 182
• Stock Exchange: NASDAQ
• Ticker Symbol: CPRX
• Website: https://catalystpharma.com

Financial Performance

In 2025, Catalyst Pharmaceuticals's revenue was $588.99 million, an increase of 19.78% compared to the previous year's $491.73 million. Earnings were $214.33 million, an increase of 30.78%.

Analyst Summary

According to one analyst, the rating for CPRX stock is "Strong Buy" and the 12-month stock price target is $35.0.

Price Target

$35.0

(51.35% upside)

Analyst Consensus: Strong Buy